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Protection of the public shall be the highest priority for the California State 
Board of Pharmacy in exercising its licensing, regulatory, and disciplinary 
functions. Whenever the protection of the public is inconsistent with other 
interests sought to be promoted, the protection of the public shall be 
paramount. 
— Business and Professions Code § 4001.1 
 
 
he California State Board of Pharmacy is a consumer protection agency 
within the state Department of Consumer Affairs (DCA). The Board is 
charged with enforcing the Pharmacy Law, Business and Professions 
Code section 4000 et seq. The Board’s regulations are located in Division 17, Title 16 of 
the California Code of Regulations (CCR).  
The Board of Pharmacy grants licenses and permits to pharmacists, advanced 
practice pharmacists, pharmacy interns, pharmacy technicians, pharmacies, pharmacy 
corporations, nonresident pharmacies, wholesale drug facilities, veterinary food-animal 
drug retailers, out-of-state distributors, clinics, hypodermic needle and syringe distributors, 
and an extensive array of associated individuals and entities. As of July 2, 2019, there were 
139,472 current licenses. The Board regulates all sales of dangerous drugs, controlled 
substances, and poisons. 
The Board consists of thirteen members, six of whom are public members. The 
Governor appoints four public members. The Senate Committee on Rules and the Speaker 
of the Assembly each appoint one public member. The remaining members are 
pharmacists, appointed by the Governor, five of whom must be active practitioners. 
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of the Board include at least one pharmacist representative from each of the following 
practice settings: an acute care hospital, an independent community pharmacy, a chain 
community pharmacy, and a long-term health care or skilled nursing facility. Furthermore, 
the Board must include a pharmacist who is a member of a labor union that represents 
pharmacists. All Board members are appointed to four-year terms.  
At this writing, the Board has one public member vacancy to be appointed by the 
Speaker of the Assembly. The Board also has two licensee vacancies to be appointed by 
the Governor. 
At this writing, the Board is still actively searching for a new Executive Officer to 
replace Virginia Herold. Since Ms. Herold’s retirement on December 28, 2018, Anne 
Sodergren has been serving as the acting the Interim Executive Officer.  
MAJOR PROJECTS 
Board Seeks Legislative Authority for 
Pharmacists to Provide Non-Opioid Medication-
Assisted Treatment 
At the Board’s May meeting [Agenda item VIII(a)], Deborah Veale, chairperson of 
the Board’s Licensing Committee, presented on addressing the nation’s opioid crisis 
through medication-assisted treatment (MAT), which helps wean patients from opioids. 
Three main medications are used for this purpose: methadone, buprenorphine and 
naltrexone. Methadone and buprenorphine are controlled substances that require a waiver 
to prescribe. Pharmacists currently are not eligible to receive this type of waiver. James J. 
Gasper, PharmD, BCPP Psychiatric and Substance Use Disorder Pharmacist with 
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Pharmacy Benefits Division, California Department of Health Care Services (DCHCS), 
presented to the Board and shared that community pharmacies can become licensed as 
opioid treatment programs (OTPs), in collaboration with a community physician that is 
licensed as an OTP, to enable pharmacists to become involved with the monitoring and 
dosing of methadone. Currently, only two licensed pharmacies in California have been 
licensed as OTPs. 
Naltrexone is a non-opioid medication used in MAT. Chairperson Veale explained 
that in Kentucky, pharmacists can provide naltrexone without a prescription, pursuant to 
state protocol that specifies criteria and procedures for initiating the dispensing and 
administering the medication to patients as part of their recovery.  
Chairperson Veale reported that the Licensing Committee discussed a draft 
statutory proposal to amend section 4052 of the Business and Professions Code to allow 
pharmacists to provide non-opioid MAT pursuant to a state protocol in California. The 
Board voted to approve the Licensing Committee’s three-pronged approach that includes: 
(1) seeking a statutory change as provided to amend 4052 to add subdivision (a)(14) and 
move forward with developing a state protocol (similar to the Kentucky protocol) for 
administering naltrexone that could be implemented immediately, (2) encouraging 
pharmacies to become licensed as OTPs for methadone dosing, and (3) directing the 
licensing committee to develop a sample collaborative practice agreement for pharmacists 
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Establishing Parameters and Fees for 
Inspections of Sterile Compounding Pharmacies 
as a Result of Remodeling of the Facility  
At the Board’s May meeting [Agenda item VIII(e)], Deborah Veale, chairperson of 
the Board’s Licensing Committee, reported that the committee discussed requirements for 
inspecting sterile compounding pharmacies at the time of issuance and renewal, and after 
a remodel of the pharmacy. Chairperson Veale explained that currently, the Board does not 
have the authority to require notification of, nor assess a fee for, an inspection as a result 
of a remodel. When the Board is notified of a remodel, it attempts to conduct the inspection 
as part of the mandatory renewal inspection. If the remodel concludes outside of the typical 
time frame for renewal inspection, the Board must perform an inspection immediately, and 
the Board currently absorbs the cost. 
After discussion, the Board voted to approve proposed language [Attachment 5] 
and seek legislation to amend Business and Professions Code section 4400 and to add 
Business and Professions Code section 4127.5 to establish notification requirements and 
authority to assess fees for inspection of remodeled sterile compounding pharmacies in 
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Board Takes Steps to Implement AB 2138 
Regarding Board Consideration of Criminal 
Records When Denying, Suspending, or Revoking 
a License 
At its May meeting [Agenda item IX(g)], the Board discussed AB 2138 (Chiu/Low) 
(Chapter 995, Statutes of 2018), which places restrictions on the acts and convictions the 
Board can consider when making a decision on an application for a license. Allen Schaad, 
chairperson of the Board’s Enforcement Committee, presented potential amendments to 
existing statutes that would restore the Board’s discretion to consider the following types 
of underlying conduct when reviewing applications for licensure: convictions of felony 
financial crimes, acts that would be grounds for denial of a federal registration to distribute 
controlled substances, acts that involve fraud in violation of state or federal law related to 
health care, convictions related to identify theft, and convictions related to the sale of 
counterfeit products. The Board voted to seek an author to make the statutory amendments 
to implement AB 2138, including language specific to criminal history.  
Chairperson Schaad also explained that AB 2138 requires the Board to develop 
criteria through the rulemaking process to determine whether a crime is “substantially 
related” to the duties of the license being sought and rehabilitation criteria. The Board voted 
to approve staff’s proposed amendments [Attachment 6] sections 1769 and 1770, Title 16 
of the CCR, and to initiate the formal rulemaking process. The Board delegated to the 
Executive Officer the authority to make any non-substantive changes and clarifying 
changes consistent with the Board’s policy direction upon recommendations of the control 
agencies. At this writing, the Board has not yet formally noticed the proposed regulations. 
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Petition from United Food & Commercial 
Workers Union (UFCW) for Rulemaking Regarding 
Pharmacist Assistance 
At its May meeting [Agenda item XIV], the Board discussed a petition it received 
from United Food & Commercial Workers Union (UFCW) recommending that the Board 
adopt regulations to further clarify the requirements created by SB 1442 (Wiener) (Chapter 
569, Statutes of 2018), which added Business and Professions Code section 4113.5 to 
require community pharmacies to have at least one other employee working at the 
pharmacy, in addition to the pharmacist, at all times. [24:1 CRLR 61–62] Within the 
petition, UCFW provided a draft of its proposed language to add to the CCR to ensure 
compliance with the new law. The Board heard testimony from pharmacists, who stated 
that the requirements set forth in SB 1442 are not being enforced. The Board voted not to 
grant the petition and instead referred the matter to the Legislation and Regulation 
Committee to further review and draft language for the Board to review and approve at a 
future meeting. 
At its July meeting [Agenda item X(a)], Gregory Lippe, chairperson of the Board’s 
Legislation and Regulation Committee, stated that the committee reviewed UFCW’s draft 
regulation proposal. Chairperson Lippe noted that the proposed language seeks to provide 
further clarification of the definition of “make available to assist,” background 
requirements for the designated personnel, and policies and procedures. The Board voted 
to recommend approval of UCFW’s proposed rulemaking to include approval of the 
proposed addition of section 1714.3, Title 16 of the CCR, and initiate the formal 
rulemaking process. The Board delegated to the Executive Officer the authority to make 
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any non-substantive changes and clarifying changes consistent with the Board’s policy 
direction upon recommendations of the control agencies. At this writing, the Board has not 
yet formally noticed the proposed regulations. 
Board Considering Employment of New Legal 
Counsel 
At its May meeting [Agenda item XVII], President Victor Law reported on the 
Board’s continued conversations with DCA pertaining to its ability to hire its own 
independent legal counsel separate from DCA legal affairs. These discussions have been 
ongoing for the past year. [24:1 CRLR 74–75]; [24:2 CRLR 58–59] President Law 
questioned what steps the Board should take to continue its search because there was no 
DCA director at the time. DCA Deputy Director for Board and Bureau Services, Chris 
Castrillo, recommended the Board schedule a meeting with Chris Schultz, acting DCA 
director, and the Deputy Director of Legal Affairs to resume these discussions. At this 
writing, the Board has not taken further action. 
Removal of Individual Licensees’ Addresses of 
Records from the Board’s Website 
At the Board’s July meeting [Agenda item VI(f)], Allen Schaad, chairperson of the 
Board’s Enforcement Committee, reported that the committee received significant public 
comment about the potential risk to licensees by having their address of record on the 
Board’s website. The Board also heard public comment in support of removing the 
individual licensee addresses from its website. Interim Executive Officer Anne Sodergren 
clarified that under California law, if the Board receives a request for a licensee’s address 
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of record, the Board is required to provide the address of record pursuant to the request. 
After discussion, the Board voted to remove all individual licensees’ addresses from the 
Board’s website. 
Pharmaceutical Compounding of Nonsterile 
Preparations 
At the Board’s July meeting [Agenda item VII(b)], Maria Serpa, chairperson of the 
Board’s Compounding Committee, reported on the committee’s discussions about 
pursuing regulations to ensure safe processes and patient safety consistent with the Board’s 
consumer protection mandate. The purpose of the regulations would be to provide clarity 
on the United States Pharmacopeia (USP) 795 Chapter, which provides standards for 
compounding quality nonsterile preparations. The USP represents the minimum national 
standard. The Board specifically considered modifications [Attachment 1] to Article 4.5, 
Title 16 of the CCR regarding pharmaceutical compounding of nonsterile preparations. 
The Board voted to modify Article 4.5, authorize the Board staff to initiate the formal 
rulemaking process with regard to the changes proposed, and authorize the executive 
officer to make changes to the language consistent with the policies indicated by the Board. 
At this writing, the Board has not yet formally noticed the proposed regulations. 
Board Settles Dispute with McKesson Corp., 
First Responders to Receive $1.5 Million Worth 
of Anti-Opioid Drug 
On August 8, 2019, the Board issued a news release announcing that the Board 
reached a legal settlement requiring healthcare company McKesson Corp. to provide 
$1.5 million worth of free naloxone, a medication that reverses opioid overdose, to first 
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responders and certain nonprofit agencies in California. According to the news release, 
“Providing naloxone to police officers, firefighters and other first responders to emergency 
calls will increase availability of the medication in California communities and help 
prevent opioid overdose deaths.” 
The Board also publicly reprimanded McKesson Corp. for failing to report 
suspicious orders of controlled substances to the Drug Enforcement Administration and 
ordered the company to pay $4,000 in investigative and enforcement costs. 
The Board’s disciplinary actions arise from McKesson Corp.’s alleged violations 
of the federal Controlled Substances Act. According to the U.S. Department of Justice, 
from 2008 to 2013, McKesson Corp. shipped increasing amounts of oxycodone and 
hydrocodone pills to pharmacies nationwide. These pills have historically been misused in 
the current opioid epidemic. 
The Board approved the stipulated settlement with McKesson Corp. on July 29, 
2019. The order took effect on August 28, 2019. 
Board Investigates Reports of Cheating on 
California Practice Standards and Jurisprudence 
(CPJE) Examination  
On September 18, 2019, the Board issued a statement, explaining that it received 
credible information indicating that the validity and reliability of the California Practice 
Standards and Jurisprudence Examination for Pharmacists (CPJE) had been compromised 
through a cheating scandal. As a result, the Board announced that it would not release the 
CPJE results until further notice, and that it had opened an investigation into the matter and 
encouraged anyone with further information to contact the Board.  
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On September 27, 2019, the Board released an update on the CPJE investigation. 
The Board stated that it would continue to investigate, and that evidence indicated 
numerous exam questions were disclosed and therefore compromised.  
On October 1, 2019, the Board posted a statement issued by American Society of 
Health-System Pharmacists (ASHP). ASHP stated that in response to the CPJE 
compromise, the Commission on Credentialing voted to recommend, and the ASHP Board 
of Directors approved, the ability for California Residency programs to grant temporary 
waivers to any California pharmacy resident who passed the North American Pharmacist 
Licensure Examination (NAPLEX); any resident who sought initial licensure in California, 
passed the NAPLEX, and practices in a Veterans Affairs facility in another state; and any 
post-graduate year two (PGY2) pharmacy resident not originally licensed in California and 
seeking licensure in California. The waivers are for the requirement that residents complete 
two-thirds of their residency as a pharmacist licensed to practice in the program’s 
jurisdiction until the Board resolves the CPJE compromise, CPJE results are released, and 
pharmacy residents are licensed. ASHP stated that during the waiver period, no California 
or Veterans Affairs program affected by the CPJE compromise will be sanctioned for not 
meeting the licensure requirement. The temporary waivers will remain in effect until the 
CPJE compromise is resolved and the Commission on Credentialing takes additional action 
to rescind the waivers. 
On October 14, 2019, the Board issued another update, indicating that it was 
continuing to investigate, and that the subversion involved instances of applicants 
removing and sharing exam questions with other applicants. The Board also stated that all 
pending CPJE results have been invalidated, and that the Board is working on a solution 
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which will allow impacted candidates a limited opportunity to retake the CPJE at no cost. 
At this writing, the matter is still ongoing. 
Board of Pharmacy Launches Billboard 
Campaign to Promote Safe Disposal of Unused 
Medications 
On September 24, 2019, the Board issued a news release regarding its “Use, Don’t 
Abuse” billboard campaign about safe disposal of unused medications. [24:1 CRLR 101] 
Acting Board President Gregory Lippe stated that the goal of the campaign is to “educate 
consumers about the importance of getting unused and unwanted drugs out of their homes 
so they don’t fall into the wrong hands.” Two billboards were installed in the Sacramento 
area, and one billboard was installed in Fresno. Two more billboards will be installed in 
Southern California. 
RULEMAKING 
Amendments to Board’s Regulations Regarding 
Naloxone Fact Sheet  
On April 26, 2019, the Board published notice of its intent to amend section 1746.3, 
Title 16 of the CCR to modify the Board’s regulations regarding the naloxone fact sheet 
that must be provided to consumers upon furnishing naloxone hydrochloride, which is set 
forth in the proposed text that the Board approved on March 27, 2018. Specifically, the 
proposed amendments provide the Board’s Executive Officer with the authority to approve 
alternative fact sheets for distribution to patients after being furnished naloxone 
hydrochloride by a pharmacist, as long as those fact sheets contain the same elements of 
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the current Board-approved fact sheet. Additionally, the proposed amendments require 
naloxone hydrochloride fact sheets provided to patients in alternate languages to be the 
current naloxone fact sheet approved and translated by the Board of Pharmacy.  
According to the Initial Statement of Reasons, the proposed regulations regarding 
the Executive Officer’s approval are the Board’s efforts “to provide flexibility to 
pharmacies and pharmacists in their business operations to present the substantive 
information in the Board-approved fact sheet in a way that is most convenient to their 
patients and business, but that still protects public safety.” The Initial Statement of Reasons 
further states that the proposed regulations regarding the translated naloxone facts sheets 
are the Board’s attempt to ensure accuracy and consistency of translation. The comment 
period for the proposed rulemaking ended on June 17, 2019.  
At its June 21, 2019 meeting [Agenda item V], the Board adopted the regulation 
language as noticed, and delegated to the Executive Officer the authority to make technical 
or non-substantive changes as may be required to complete the rulemaking file. At this 
writing, the rulemaking file is undergoing review by the Business, Consumer Services and 
Housing Agency. 
Amendments to Board’s Fee Schedule 
On April 26, 2019, the Board published notice of its intent to amend section 1749, 
Title 16 of the CCR to update the Board’s fee schedule, which is set forth in the proposed 
text that the Board approved on December 14, 2018. [24:2 CRLR 64] Specifically, the 
proposed amendments increase application, renewal, and other fees to their statutory 
maximums. The proposal for a fee increase follows a DCA analysis of the Board’s fund 
condition and fee structure in November 2015, which the Board requested. The analysis 
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found the current level of fees insufficient to keep the Board’s fund solvent and that fees 
needed to be adjusted to reflect the Board’s actual cost in providing service and processing 
each license type. 
According to the Initial Statement of Reasons, the proposed regulations are the 
Board’s efforts to eliminate the structural imbalance and begin restoring the board’s reserve 
fund. The Initial Statement of Reasons further states: “Raising fees to the statutory 
maximum will ensure that those fees cover the expenses associated with protecting the 
public through licensing, regulating, compliance, and disciplining the licensees of the 
pharmacy industry.” The comment period for the proposed rulemaking ended on June 10, 
2019.  
At its June 21, 2019 meeting [Agenda item IV], the Board adopted the regulation 
language as noticed, and delegated to the Executive Officer the authority to make technical 
or non-substantive changes as may be required to complete the rulemaking file. At this 
writing, the rulemaking file is undergoing review by the Office of Administrative Law 
(OAL). 
Amendments to Regulations Governing Remote 
Dispensing Pharmacy Technicians 
At its June 21, 2019 meeting [Agenda item VI], the Board discussed and considered 
its proposal to add section 1793.9, Title 16 of the CCR, to implement AB 401 (Aguiar-
Curry) (Chapter 548, Statutes of 2017), which established the Board’s authority to issue a 
remote dispensing site pharmacy (RDSP) license in order to increase access to prescription 
medication and pharmacist care for Californians living in rural areas. The Board originally 
approved the proposed text for rulemaking on July 26, 2017. 
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The Board originally noticed its proposed addition on April 12, 2019, in order to 
establish the specific minimum requirements for pharmacy technicians working in a RDSP, 
including a certification issued by an approved certifying program; an associate degree in 
Pharmacy Technology, any bachelor’s degree, or completion of a board approved training 
program; and a minimum of 1,000 hours of work experience in the three years prior to 
working at a RDSP. [24:2 CRLR 58] The comment period for the proposed rulemaking 
ended on May 28, 2019. 
At the June 21, 2019 meeting [Agenda item VI], the Board deferred action on the 
regulatory language in light of then pending legislation, AB 690 (Aguiar-Curry) (Chapter 
679, Statutes of 2019), which establishes these requirements in statutory form, as discussed 
below (see LEGISLATION). 
Board Notices Proposed Amendments to Duty to 
Consult Regulations 
On August 9, 2019, the Board published notice of its intent to amend section 
1707.2, Title 16 of the CCR to clarify and specify the standards of the “Duty to Consult” 
to all pharmacies, including mail order pharmacies and pharmacies that deliver 
medications, which is set forth in the proposed text that the Board approved on May 2, 
2018. [24:1 CRLR 78] 
According to the Initial Statement of Reasons, the proposed regulations are the 
Board’s efforts to provide a direct means for patients whose prescriptions are dispensed 
through the mail to access a pharmacist to receive vital prescription drug information. The 
Initial Statement of Reasons further states that “a patient should have ready access to a 
pharmacist for purposes of consultation even when drugs are shipped to the consumer.” 
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The comment period for the proposed rulemaking ended on September 30, 2019. At this 
writing, the Board has taken no further action.  
Abandonment of Applications 
On September 6, 2019, the Board published notice of its intent to amend section 
1706.2, Title 16 of the CCR to consolidate all board license types into two broad categories, 
which are set forth in the proposed text that the Board approved on February 6, 2018. 
Specifically, the proposed amendments consolidate the license types into two categories: 
(1) a premises license and (2) an individual license, with an exception for pharmacist 
examination and licensure and pharmacy intern applicants, as these licensing programs 
have specialized requirements.  
According to the Initial Statement of Reasons, the proposed regulations are the 
Board’s efforts “to provide clarity to the regulated public with respect to the criteria used 
by the [B]oard to deem an application abandoned.” The Initial Statement of Reasons further 
states that the proposed regulations are the Board’s attempt to increase its efficiency as the 
Board would no longer need to update its regulations to specify each new premises or 
individual license type. The comment period for the proposed rulemaking ended on 
October 14, 2019. At this writing, the Board staff is preparing final rulemaking documents.  
LEGISLATION 
AB 690 (Aguiar-Curry), as amended July 1, 2019, amends sections 4062 and 4132 
of the Business and Professions Code to establish qualifications for a pharmacy technician 
working at a remote dispensing site pharmacy. The bill also allows for a pharmacy license 
to be transferred in a declared state of emergency. According to the author, “AB 690 will 
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make telepharmacy a reality in areas of the state that currently do not have pharmacy 
access. This will provide opportunities for improved patient education, increased 
medication adherence, and better overall health outcomes in these communities.”  
Governor Newsom signed AB 690 on October 9, 2019 (Chapter 679, Statutes of 
2019).  
AB 973 (Irwin), as amended May 13, 2019, adds section 4126.8 to the Business 
and Professions Code, to require that the compounding of drug preparations by a pharmacy 
for furnishing, distribution, or use shall be consistent with standards established in the most 
recent pharmacy compounding chapters of the United States Pharmacopeia—National 
Formulary, including relevant testing and quality assurance. According to the author, the 
bill “will provide clarity for the standard of pharmacy compounding that the California 
Board of Pharmacy can utilize to oversee the practice of drug compounding.”  
Governor Newsom signed AB 973 on August 30, 2019 (Chapter 184, Statutes of 
2019). 
AB 1723 (Wood), as amended March 18, 2019, amends section 4180 to the 
Business and Professions Code, to update the pharmacy law relating to the purchase of 
drugs at wholesale to reflect that clinics operated by a primary care community or free 
clinic may be open up to forty hours per week. According to the author, this bill will 
conform the Pharmacy Law to the state law referenced in the Business and Professions 
Code.  
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AB 1803 (Committee on Health), as introduced on February 28, 2019, amends, 
repeals, and adds section 4079, and repeals section 4079.5, of the Business and Professions 
Code to extend the deadline for pharmacies to comply with specified 2018 legislation.  AB 
315 (Wood) (Chapter 905, Statutes of 2018) and AB 2863 (Nazarian) (Chapter 770, 
Statutes of 2018) added section 4079 to require a pharmacy, in the event that the copay of 
a particular patient’s prescription is more than the point of sale price, to submit the claim 
for the lesser amount to the health plan or insurer to apply to the deductible and/or out of 
pocket max.  This bill extends the deadline for compliance from January 1, 2019 to January 
1, 2020. According to the author, “this bill will delay implementation of the requirement 
for pharmacies to submit claims, when patients pay a lower point of sale cost, to the 
patient’s health plan or insurance company.” Further stating, “[t]he one-year delay will 
give pharmacies more time to develop mechanisms to comply with the law.”  
Governor Newsom signed AB 1803 on July 12, 2019 (Chapter 114, Statutes of 
2019). Designated as an urgency bill, it became effective the same day.  
SB 159 (Wiener), as amended September 5, 2019, as it applies to the Board of 
Pharmacy, amends section 4052 and adds sections 4052.02 and 4052.03 to the Business 
and Professions Code, to authorize pharmacists to furnish combination antiretroviral drug 
treatments that are medically necessary for the prevention of AIDS/HIV, including 
preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP), in accordance with 
protocols established by this bill. The bill also allows a pharmacist to furnish at least a 
thirty-day, and up to a sixty-day, supply of PrEP; deletes the requirement for a pharmacist 
to order a kidney function test; and prohibits a health care service plan from covering PrEP 
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furnished by a pharmacist in excess of a 60-day supply to a single patient once every two 
years, unless the pharmacist has been directed otherwise by a prescriber.  
According to the author, “[a]llowing pharmacists to furnish PrEP and PEP without 
a prescription will expand access, help increase the number of individuals who use these 
HIV preventatives, and will help California achieve its goal to end new HIV infections.” 
According to the Assembly Appropriations Committee, this bill will result in costs to the 
Board of Pharmacy of $65,000 in fiscal year 2020–21 and $60,000 in 2021–22 and ongoing 
for staffing costs and information technology costs. Under the bill, the Board, by July 1, 
2020, must adopt emergency regulations to implement sections 4052.02 and 4052.03 in 
accordance with the Centers for Disease Control and Prevention guidelines and consult 
with the Medical Board of California in developing pursuant regulations. At its May 
meeting [Agenda item XV], the Board voted to support the bill.  
Governor Newsom signed SB 159 on October 7, 2019 (Chapter 532, Statutes of 
2019). 
SB 569 (Stone), as amended July 2, 2019, is a Board-sponsored bill that adds 
section 11159.3 to the Health and Safety Code, to establish prescription content 
requirements for a pharmacist to furnish a controlled substance without a standard 
prescription form during a declared state of emergency. Specifically, if the Board issues a 
notice that the Board is waiving portions of the law during a declared local, state, or federal 
emergency, a pharmacist may fill a prescription for a controlled substance for use by a 
patient who cannot access medications as a result of the emergency, regardless of whether 
the prescription form meets state law, if specified conditions apply. Additionally, a 
pharmacist must meet certain requirements in order to furnish a controlled substance during 
 
78 
California Regulatory Law Reporter ♦ Volume 25, No. 1 (Fall 2019) ♦  
Covers April 16, 2019–October 15, 2019 
an emergency, including limiting the prescription to no greater than the amount needed for 
a seven-day supply, requiring the patient to demonstrate an inability to access medications, 
and prohibiting refills.  
In its letter to the Senate Business, Professions, and Economic Development 
Committee, the Board stated:  
As part of its consumer protection role, the board undertook review of recent 
declared disasters that have negatively impacted Californians to determine 
if gaps in legal provisions exist.... One of the challenges noted [from 
pharmacists involved in relief efforts] was a barrier to access to controlled 
substances caused by the security forms required for such medications. As 
the board lacks the authority to waive a provision of the Health and Safety 
Code during a declared disaster and being mindful of the opioid epidemic, 
the board’s proposal strikes a balance between removing the barrier to 
access to medications during the initial phases of a disaster and preventing 
the possible exploitation of such an exemption.  
Governor Newsom signed SB 569 on October 9, 2019 (Chapter 705, Statutes of 
2019).  
SB 655 (Roth), as amended April 11, 2019, is a Board-sponsored bill that amends 
sections 4115.5, 4163, and 4200 of; amends, repeals, and adds section 4400 of; and adds 
section 4211 to the Business and Professions Code to increase the number of hours required 
for a pharmacy technician training program, modify procurement rules for a reverse 
distributor (an entity that collects and processes unwanted or unused drugs), update renewal 
requirements for an advanced practice pharmacist, require licensing fees for government 
entities, and make additional technical changes. According to the author, the bill will “bring 
conformity to pharmacy law, ensure minimum competency, remove barriers to licensure, 
and seek alignment with stipulated requirements.”  
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Legislative Bills That Died 
The following bills died in committee or otherwise failed to be enacted in 2019: 
AB 387 (Gabriel), which would have required physicians and surgeons to indicate the 
purpose for a drug or device on its prescription, unless the patient chose to opt out; AB 544 
(Brough), relating to maximum renewal fees for inactive licenses; SB 476 (Stone), relating 
to disciplinary action for pharmacists-in-charge; SB 491 (Stone), relating to pharmacy 
compounding services;  SB 617 (Glazer), relating to pharmacy technician supervision; and 
SB 650 (Rubio), relating to cancer medication recycling. 
RECENT MEETINGS 
At its May meeting [Agenda item VII], the Board reelected President Victor Law, 
Vice President Gregory N. Lippe, and Treasurer Allen Schaad as officers. At its July 
meeting [Agenda item I], however, the Board announced the resignation of President 
Victor Law. Vice President Gregory Lippe advised that he act as the Acting President until 
the Board conducts new elections. New elections were supposed to take place at the 
Board’s September meeting [Agenda item IV], but there was not a quorum, and the Board 
was therefore unable to vote. At this writing, Mr. Lippe is still serving as the Acting 
President.  
At the Board’s May meeting [Agenda item XVI], President Law reported that at its 
March meeting [Agenda item II], the Board interviewed four candidates for the position of 
Executive Officer. He stated that during closed session, the Board selected a candidate and 
submitted a letter to DCA, seeking approval of the candidate. President Law noted that 
until DCA approves the Board’s request, the matter will remain confidential. At the 
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Board’s July meeting [Agenda item I], acting President Gregory Lippe reported the Board 
made a request to DCA for an update on the Executive Officer position. He stated that once 
an update becomes available, the Board will release an announcement. 
At its May meeting [Agenda item XI(l)], President Law explained that pursuant to 
Business and Professions Code section 139, the Board is required to periodically complete 
an occupational analysis which serves as the basis for the California Practice Standards and 
Jurisprudence Examination for Pharmacists (CPJE). President Law reported that the 
Competency Committee initiated development of a job analysis questionnaire to complete 
the occupational analysis with the Board’s contracted psychometric firm. The job analysis 
questionnaire will consist of duties a licensed pharmacist is authorized to perform in 
California. As part of the questionnaire, participants will assess the importance of each 
duty as well as the frequency the duty is performed. President Law stated that pharmacists 
who complete the job analysis questionnaire have historically been awarded three hours of 
CE credit through an action of the board. The Board voted to again approve three hours of 
CE credit to pharmacists who complete the job analysis questionnaire.  
